Key result
Nifedipine GITS did not slow coronary calcium progression compared to placebo, with a non-significant trend toward freedom from new calcified lesions.
Why the study?
Does nifedipine GITS added to standard therapy slow down the progression of calcium or the development of new atherosclerotic lesions in patients with chronic symptomatic coronary artery disease?
RCT (n=518)
Does nifedipine GITS added to standard therapy slow down the progression of calcium or the development of new atherosclerotic lesions in patients with chronic symptomatic coronary artery disease?
Nifedipine GITS does not significantly slow the progression of coronary calcification in patients with stable angina pectoris.
Answers are grounded in this paper and cite their sources.
Nifedipine GITS does not slow coronary calcium progression in stable CAD; confirms no benefit on this surrogate endpoint.
AIMS: The objective of the Coronary Calcification (CC) study was to determine in patients with chronic symptomatic coronary artery disease, if, in addition to standard therapy, nifedipine GITS, relative to placebo, would arrest or slow down the progression of calcium or the development of new atherosclerotic lesions in the coronary arteries. METHODS AND RESULTS: The CC study was part of the ACTION trial. Multi-slice computerized tomography was used to measure and track the progression of CC. Five hundred and eighteen patients were included in this study. The changes in calcium score from baseline every 24 months, over a period of between 4.5 and 6 years, were similar in the nifedipine and placebo treatment groups (p = 0.8). Compared to placebo, more patients in the nifedipine group (71 vs. 60%) were free of new calcified atherosclerotic lesions during follow-up(p = 0.095). CONCLUSION: Nifedipine GITS was not effective in slowing down the progression of calcium in advanced atherosclerotic plaques in patients with stable angina pectoris. Although statistically not significant, Nifedipine demonstrated a trend in slowing down the development of new atherosclerotic lesions.
No takes yet. Share an insight, caveat, or question.
Motro et al. (2006) conducted an RCT in Chronic symptomatic coronary artery disease (stable angina pectoris) (n=518). Nifedipine GITS vs. Placebo was evaluated on Freedom from new calcified atherosclerotic lesions (p=0.095). Nifedipine GITS did not slow coronary calcium progression compared to placebo, with a non-significant trend toward freedom from new calcified lesions.
Synapse has enriched 10 related papers. Consider them for comparative context: